Pharmacokinetics of Gnrh Continuous Agonist Usmmle
Use of GnRH Agonist in Dogs Affected with Leishmaniosis
1
Department of Veterinary Sciences, University of Messina, 98168 Messina, Italy
2
BIOGENE Veterinary Diagnostic Center, Via Giacomo Leopardi, 50, 95127 Catania, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Cynthia M. Otto
Received: 8 January 2021 / Revised: 1 February 2021 / Accepted: 2 February 2021 / Published: 7 February 2021
Simple Summary
Most parasitic diseases, including Leishmania infection, often show more severe clinical signs in males than females. This is related to a different immune response, presumably related to testosterone activity. The present study aimed to evaluate the efficacy of a gonadotropin-releasing hormone GnRH agonist implant (deslorelin acetate) in association with meglumine antimoniate plus allopurinol in the treatment of dogs affected by Leishmania. Deslorelin acetate is a GnRH agonist, widely used for chemical reversible sterilization in male dogs, inducing testosterone suppression. Dogs treated with deslorelin show a significant decrease of clinical scores and serological test, suggesting a possible employ of GnRH agonist in the treatment of canine leishmaniosis.
Abstract
Sex-associated hormones such as testosterone have been demonstrated to modulate immune responses, which can result in different disease outcomes. The present study was aimed at evaluating the efficacy of a gonadotropin-releasing hormone GnRH agonist implant as deslorelin acetate in association with meglumine antimoniate plus allopurinol in dogs with canine leishmaniosis (CanL). Twenty-two dogs with CanL confirmed by clinical findings and laboratory tests were included in the study. Dogs were randomized into two groups. A control group (CTR, n = 12) was treated with meglumine antimoniate 50 mg/kg SC q 12 h for 28 days plus allopurinol at 10 mg/kg PO q 12 h for the whole study period (six months). An experimental group was treated with allopurinol and meglumine antimoniate, plus an implant of 4.7 mg deslorelin acetate (DES, n = 10). The animals were observed for three months, during which clinical evaluation, indirect fluorescent antibody test (IFAT) titre and testosterone assay were performed on time at day (D)0, 90 and 180. A significantly lower clinical score was recorded in DES than in CTR (p < 0.01) at D90 and D180 (p < 0.01). After 180 days of treatment (D180), a significant reduction of mean levels of IFAT was observed in the DES group (p = 0.03). A highly significant reduction of testosterone (p = 0.01) was observed in the DES group during the study. No statistical correlation between clinical scores, IFAT titres and testosterone within two groups was observed. Data suggested that the agonist of GnRH may be useful in the treatment of CanL. View Full-Text
► ▼ Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Share and Cite
MDPI and ACS Style
Pugliese, M.; Biondi, V.; Quartuccio, M.; Cristarella, S.; Emmanuele, G.; Marino, G.; Liotta, L.; Passantino, A. Use of GnRH Agonist in Dogs Affected with Leishmaniosis. Animals 2021, 11, 432. https://doi.org/10.3390/ani11020432
AMA Style
Pugliese M, Biondi V, Quartuccio M, Cristarella S, Emmanuele G, Marino G, Liotta L, Passantino A. Use of GnRH Agonist in Dogs Affected with Leishmaniosis. Animals. 2021; 11(2):432. https://doi.org/10.3390/ani11020432
Chicago/Turabian Style
Pugliese, Michela, Vito Biondi, Marco Quartuccio, Santo Cristarella, Giovanni Emmanuele, Gabriele Marino, Luigi Liotta, and Annamaria Passantino. 2021. "Use of GnRH Agonist in Dogs Affected with Leishmaniosis" Animals 11, no. 2: 432. https://doi.org/10.3390/ani11020432
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click here.
Multiple requests from the same IP address are counted as one view.
Source: https://www.mdpi.com/2076-2615/11/2/432
0 Response to "Pharmacokinetics of Gnrh Continuous Agonist Usmmle"
Enviar um comentário